Publication | Closed Access

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Dose Expansion PartsDose EscalationMedicinePathologyCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerMolecular OncologyPhase 1–2